Profile data is unavailable for this security.
About the company
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.
- Revenue in USD (TTM)1.66m
- Net income in USD-87.30m
- Incorporated2016
- Employees75.00
- LocationShattuck Labs Inc500 W. 5Th Street, Suite 100AUSTIN 78701United StatesUSA
- Phone+1 (512) 900-4690
- Websitehttps://www.shattucklabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C4 Therapeutics Inc | 20.76m | -132.49m | 443.85m | 145.00 | -- | 1.59 | -- | 21.38 | -2.67 | -2.67 | 0.4181 | 4.07 | 0.0514 | -- | 3.13 | 143,144.80 | -32.82 | -25.91 | -36.80 | -29.45 | -- | -- | -638.34 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| Theravance Biopharma Inc | 57.42m | -55.19m | 445.29m | 99.00 | -- | 2.07 | -- | 7.75 | -0.9704 | -0.9704 | 1.04 | 4.43 | 0.1161 | -- | 3.35 | 580,040.40 | -11.16 | -40.51 | -11.79 | -48.50 | -- | -- | -96.11 | -305.27 | -- | -- | 0.00 | -- | 11.84 | -0.9956 | 40.54 | -- | -19.24 | -- |
| ACELYRIN Inc | 0.00 | -381.64m | 449.53m | 130.00 | -- | 0.6814 | -- | -- | -10.84 | -10.84 | 0.00 | 6.71 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -489.21 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 2.81m | -97.34m | 450.89m | 76.00 | -- | 1.92 | -- | 160.74 | -1.59 | -1.59 | 0.0458 | 3.80 | 0.0116 | -- | 1.68 | 36,907.89 | -40.19 | -50.55 | -42.88 | -55.91 | -- | -- | -3,470.05 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Humacyte Inc | 0.00 | -110.78m | 454.90m | 183.00 | -- | 29.24 | -- | -- | -1.07 | -1.07 | 0.00 | 0.1307 | 0.00 | -- | -- | 0.00 | -66.63 | -- | -75.23 | -- | -- | -- | -- | -- | -- | -88.38 | 0.5819 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Third Harmonic Bio Inc | 0.00 | -30.82m | 461.29m | 30.00 | -- | 1.69 | -- | -- | -0.9461 | -0.9461 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -10.70 | -- | -10.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| IGM Biosciences Inc | 2.13m | -246.42m | 467.94m | 224.00 | -- | 2.30 | -- | 219.69 | -4.81 | -4.81 | 0.0407 | 3.46 | 0.0046 | -- | -- | 9,508.93 | -52.60 | -44.66 | -58.00 | -48.20 | -- | -- | -11,568.83 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Shattuck Labs Inc | 1.66m | -87.30m | 470.00m | 75.00 | -- | 3.23 | -- | 283.65 | -2.05 | -2.05 | 0.0389 | 3.06 | 0.0091 | -- | -- | 22,093.33 | -47.85 | -29.14 | -53.15 | -32.42 | -- | -- | -5,268.44 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Fate Therapeutics Inc | 63.53m | -160.93m | 486.64m | 181.00 | -- | 1.15 | -- | 7.66 | -1.63 | -1.63 | 0.6456 | 3.74 | 0.1049 | -- | 3.15 | 351,011.10 | -26.56 | -31.82 | -30.40 | -36.05 | -- | -- | -253.30 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| PetIQ Inc | 1.10bn | 2.13m | 491.19m | 1.93k | 269.35 | 2.20 | 10.00 | 0.4457 | 0.0614 | 0.0614 | 35.69 | 7.52 | 1.31 | 5.63 | 8.46 | 570,079.10 | 0.301 | -4.32 | 0.3777 | -5.23 | 22.94 | 20.05 | 0.2304 | -3.66 | 1.43 | 1.74 | 0.6671 | -- | 19.58 | 15.83 | 104.42 | -- | 4.96 | -- |
| Applied Therapeutics Inc | 9.99m | -119.76m | 492.38m | 25.00 | -- | -- | -- | 49.27 | -1.42 | -1.42 | 0.1288 | -0.202 | 0.2145 | -- | -- | 399,720.00 | -257.01 | -140.37 | -- | -240.93 | -- | -- | -1,198.47 | -4,476.42 | -- | -- | -- | -- | -- | -- | -45.15 | -- | -- | -- |
| Astria Therapeutics Inc | 0.00 | -72.89m | 494.13m | 59.00 | -- | 2.50 | -- | -- | -2.34 | -2.34 | 0.00 | 5.92 | 0.00 | -- | -- | 0.00 | -30.04 | -64.48 | -31.37 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Arbutus Biopharma Corp | 18.14m | -72.85m | 495.48m | 73.00 | -- | 4.41 | -- | 27.31 | -0.4386 | -0.4386 | 0.1093 | 0.6241 | 0.1068 | -- | 11.60 | 248,506.80 | -42.88 | -52.62 | -51.22 | -58.11 | -- | -- | -401.57 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -62.74m | 500.00m | 129.00 | -- | -- | -- | -- | -1.68 | -1.68 | 0.00 | -6.83 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -3.73 | -- | -- | -- |
Data as of Apr 25 2024. Currency figures normalised to Shattuck Labs Inc's reporting currency: US Dollar USD
51.45%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 7.07m | 14.89% |
| Redmile Group LLCas of 28 Mar 2024 | 5.62m | 11.83% |
| Prosight Management LPas of 31 Dec 2023 | 2.78m | 5.86% |
| Adage Capital Management LPas of 17 Jan 2024 | 2.58m | 5.43% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 1.64m | 3.45% |
| The Clark Estates, Inc.as of 31 Dec 2023 | 1.48m | 3.11% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 1.30m | 2.74% |
| Point72 Asset Management LPas of 31 Dec 2023 | 670.44k | 1.41% |
| Laurion Capital Management LPas of 31 Dec 2023 | 661.04k | 1.39% |
| Maven Investment Partners US Ltd. (US)as of 31 Dec 2023 | 633.88k | 1.34% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
